SCHEMBL989470

SCHEMBL989470

Fc1ccc(-c2ccn(C(c3ccccc3)(c3ccccc3)c3ccccc3)n2)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 4/20 0.40
TP53 P04637 1/20 0.40
MDM2 Q00987 1/20 0.40
F2RL3 Q96RI0 1/20 0.37
KMO O15229 2/20 0.37
MLNR O43193 1/20 0.36
NR1I2 O75469 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
TBXA2R P21731 1/20 0.36
CCKBR P32239 1/20 0.36
OPRK1 P41145 1/20 0.36
SLC6A3 Q01959 1/20 0.36
KCNH2 Q12809 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
ACSS2 Q9NR19 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3844590 0.86 HSD11B1 (0.44) KMOACSS2KCNN4CYP2C9
SCHEMBL27623829 0.78 MAOB (0.40) GRM5TP53F2RL3KMOALDH1A1
SCHEMBL3847454 0.75 MAOB (0.40) GRM5KMOACSS2KCNN4ALDH1A1
SCHEMBL3846649 0.74 HSD11B1 (0.41) TP53KCNN4ALDH1A1
SCHEMBL989421 0.74 ADORA1 (0.36) GRM5TP53MDM2F2RL3MLNR
SCHEMBL28044048 0.74 METAP2 (0.42) TP53ALDH1A1CYP3A4CYP2C19
SCHEMBL5800759 0.73 KMT2A (0.52) TP53L3MBTL1KCNN4ALDH1A1
SCHEMBL26111723 0.72 SCN4A (0.47) GRM5TP53MDM2F2RL3KMO
SCHEMBL3845533 0.71 TP53 (0.36) GRM5TP53MDM2F2RL3ADORA2A
SCHEMBL27930520 0.71 CYP11B1 (0.40) TP53MLNRNR1I2ADORA3TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863310-B2 Kinase inhibitors ELI LILLY AND COMPANY (US) 2011-01-04 US disclosed
EP-2048142-A2 Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof Eisai R&D Management Co., Ltd. (JP) 2009-04-15 EP disclosed
US-20080227839-A1 Kinase Inhibitors ELI LILLY AND COMPANY 2008-09-18 US disclosed
EP-1382603-B1 NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF EISAI R&D MAN CO LTD (JP) 2008-07-23 EP disclosed
EP-1720862-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2006-11-15 EP disclosed
US-7074801-B1 Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof EISAI CO., LTD. (JP) 2006-07-11 US disclosed
WO-2005080380-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2005-09-01 WO disclosed
EP-1382603-A1 NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF Eisai Co., Ltd. (JP) 2004-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227839-A1 Kinase Inhibitors ABL1, MAP3K20, MAP3K19 GRM5 2763/4885TP53 392/4885MDM2 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.